Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
South Korea · Delayed Price · Currency is KRW 505,000
+1,000 (0.20%)
Apr 10, 2026, 3:30 PM KST
Sam Chun Dang Pharm. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 231,805 | 210,924 | 192,669 | 177,335 | 167,275 |
Other Revenue | -0 | -0 | - | -0 | - |
| 231,805 | 210,924 | 192,669 | 177,335 | 167,275 | |
Revenue Growth (YoY) | 9.90% | 9.47% | 8.65% | 6.01% | 0.25% |
Cost of Revenue | 122,714 | 111,639 | 96,063 | 87,705 | 84,440 |
Gross Profit | 109,091 | 99,285 | 96,605 | 89,630 | 82,835 |
Selling, General & Admin | 86,884 | 84,552 | 78,291 | 68,471 | 62,980 |
Research & Development | 8,529 | 7,837 | 5,042 | 5,471 | 32,389 |
Amortization of Goodwill & Intangibles | 892.23 | 11.78 | 11.6 | 10.61 | 26.77 |
Other Operating Expenses | 1,505 | 1,313 | 1,145 | 1,132 | 1,090 |
Operating Expenses | 100,766 | 96,722 | 87,046 | 77,062 | 98,124 |
Operating Income | 8,325 | 2,563 | 9,560 | 12,569 | -15,289 |
Interest Expense | -979.97 | -382.54 | -2,577 | -2,793 | -1,897 |
Interest & Investment Income | 3,509 | 4,606 | 2,788 | 2,121 | 1,435 |
Currency Exchange Gain (Loss) | 471.65 | 1,552 | -409.16 | 445.33 | 130.23 |
Other Non Operating Income (Expenses) | 359.22 | -374.91 | -16,611 | -2,634 | 1,546 |
EBT Excluding Unusual Items | 11,686 | 7,964 | -7,249 | 9,708 | -14,074 |
Gain (Loss) on Sale of Investments | 1,464 | 2,777 | 4,357 | 1,422 | 287.01 |
Gain (Loss) on Sale of Assets | 5,221 | 2,267 | 1,455 | 810.73 | 9,617 |
Asset Writedown | -5,853 | -1,970 | -3,112 | -3,021 | -15,380 |
Pretax Income | 12,518 | 11,038 | -4,549 | 8,920 | -19,549 |
Income Tax Expense | 487.74 | 16,116 | -360.77 | 87.7 | -9,188 |
Earnings From Continuing Operations | 12,030 | -5,078 | -4,188 | 8,832 | -10,361 |
Minority Interest in Earnings | -6,768 | -5,838 | -6,195 | -2,994 | -6,194 |
Net Income | 5,262 | -10,916 | -10,383 | 5,838 | -16,555 |
Net Income to Common | 5,262 | -10,916 | -10,383 | 5,838 | -16,555 |
Shares Outstanding (Basic) | 23 | 23 | 22 | 22 | 22 |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 22 | 22 |
Shares Change (YoY) | 1.10% | 1.20% | 3.12% | - | 1.86% |
EPS (Basic) | 226.00 | -474.00 | -463.03 | 264.52 | -750.19 |
EPS (Diluted) | 226.00 | -474.00 | -463.03 | 264.52 | -750.19 |
Free Cash Flow | -36,353 | 4,748 | 16,662 | -3,252 | -22,589 |
Free Cash Flow Per Share | -1561.38 | 206.18 | 732.16 | -147.38 | -1023.60 |
Gross Margin | 47.06% | 47.07% | 50.14% | 50.54% | 49.52% |
Operating Margin | 3.59% | 1.21% | 4.96% | 7.09% | -9.14% |
Profit Margin | 2.27% | -5.17% | -5.39% | 3.29% | -9.90% |
Free Cash Flow Margin | -15.68% | 2.25% | 8.65% | -1.83% | -13.50% |
EBITDA | 19,319 | 11,592 | 17,990 | 20,220 | -8,548 |
EBITDA Margin | 8.33% | 5.50% | 9.34% | 11.40% | -5.11% |
D&A For EBITDA | 10,993 | 9,029 | 8,430 | 7,651 | 6,741 |
EBIT | 8,325 | 2,563 | 9,560 | 12,569 | -15,289 |
EBIT Margin | 3.59% | 1.21% | 4.96% | 7.09% | -9.14% |
Effective Tax Rate | 3.90% | 146.01% | - | 0.98% | - |
Advertising Expenses | 2,937 | 4,005 | 3,756 | 2,460 | 1,782 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.